Accès ouvert
2023
article
OpenAlex
Steven Kymes, Neal L. Oden, Paul VanVeldhuisen, Ingrid U. Scott et autres
Importance: Retinal vein occlusion is the second most common retinal vascular disease. Bevacizumab was demonstrated in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) to be noninferior to aflibercept with respect to visual acuity in study participants with macular …
us
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Ingrid U. Scott, Neal L. Oden, Paul VanVeldhuisen, Michael S. Ip et autres
Importance: Intravitreal anti-vascular endothelial growth factor (VEGF) injections are commonly used to treat eyes with macular edema secondary to hemiretinal vein occlusion (HRVO) or central retinal vein occlusion (CRVO). Information on whether differences exist in outcomes after anti-VEGF therapy can help guide …
us
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Ahmad A. Aref, Ingrid U. Scott, Paul VanVeldhuisen, Jacquie King et autres
IMPORTANCE: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections are used to treat a variety of posterior segment conditions, including some associated with glaucoma, such as macular edema due to central retinal vein occlusion (CRVO). Therefore, information regarding intraocular pressure (IOP)-related events associated …
us
(code pays fourni par la source)
2008
article
OpenAlex
Eileen Guan
Objective To evaluate the efficacy of Ganciclovir plus andrographolide for hand-foot-mouth disease. Methods Eighty-five patients were randomly divided into two groups: treatment group(44 cases),Ganciclovir plus andrographolide were given;control group(41),Ribavirin and vitamin C. Results The outcome was better in treatment group than the …